Table 1.

CD47 antagonists currently in clinical trials for hematologic malignancies.

Agents	Diseases	Open Clinical Trials	Phase	Status and Results
Hu5F9-G4	AML	NCT026783338—CAMELLIA: anti-CD47 antibody therapy in relapsed/refractory AML	I	- Recruitment completed - Hu5F9-G4 infusion in refractory AML patients led to hemoglobin decline and increased transfusion requirements [99].
Hu5F9-G4 + Atezolizumab	AML	NCT03922477—trial of Hu5F9-G4 with atezolizumab in patients with relapsed and/or refractory AML	Ib	- Recruiting
Hu5F9-G4 +/– Azacitidine	AML MDS	NCT03248479—trial of Hu5F9-G4 monotherapy or with azacytidine in hematologic malignancies	I	- Recruiting
Hu5F9-G4 + Rituximab	NHL	NCT02953509—trial of Hu5F9 with rituximab in relapsed/refractory NHL	Ib/II	- Recruiting - Hu5F9-G5 plus rituximab showed promising activity in NHL patients with no clinically significant safety events [97].
Hu5F9-G4 + Rituximab + Acalabrutinib	NHL	NCT03527147—PRISM: platform study for the treatment of relapsed/refractory aggressive NHL	I	- Recruiting
CC-90002	AML MDS	NCT02641002—trial of CC-90002 in patients with AML or high risk MDS	I	- Terminated - Monotherapy did not show encouraging profile for further studies
CC-90002 +/– Rituximab	Solid and hematologic tumors	NCT02367196—trial of CC-90002 in patients with advanced solid tumors and hematologic malignancies	I	- Recruiting
TTI-621 +/– Rituximab or Nivolumab	Solid and hematologic tumors	NCT02663518—trial of TTI-621 alone or with other agents for hematologic malignancies and selected solid tumors	I	- Recruiting - TTI-621 showed therapeutic efficacy for SS patients [98].
ALX-148 +/– Pembrolizumab or Trastuzumab or Rituximab	Solid and hematologic tumors	NCT03013218—trial of ALX-148 in patients with advanced solid tumors and lymphoma	I	- Recruiting

Abbreviations: AML—acute myeloid leukemia; MDS—myelodysplastic syndrome; NHL—Non-Hodgkin’s lymphoma; SS—Sézary syndrome.